Literature DB >> 8298818

Study of the mechanism of the relaxant action of (+)-glaucine in rat vas deferens.

F Orallo1, A Fernández Alzueta, M I Loza, N Vivas, A Badía, M Campos, M A Honrubia, M I Cadavid.   

Abstract

1. Effects of the aporphinoid alkaloid, (+)-glaucine, on rat vas deferens were investigated. 2. (+)-Glaucine (2-18 microM) competitively inhibited contractions induced by noradrenaline and methoxamine with a pA2 value of about 6. 3. (+)-Glaucine (2 and 18 microM) did not change the accumulation of tritium during incubation of the vas deferens with [3H]-noradrenaline. 4. (+)-Glaucine (0.3 nM-0.1 mM) inhibited specific [3H]-prazosin binding to membranes from rat vas deferens with a pKi value of 6.63, which is close to the pA2 value obtained against noradrenaline and methoxamine in functional studies. 5. In electrically-stimulated rat vas deferens, (+)-glaucine (0.3-10 microM) enhanced twitch contractions and competitively antagonized the inhibitory effect of clonidine with a pA2 value of 5.91. 6. In tissues incubated in depolarizing calcium-free high-potassium medium, (+)-glaucine (30-80 microM) inhibited Ca(2+)-induced contractions with depression of the maximal response at higher doses and with a pD'2 value of 3.65. Furthermore, (+)-glaucine (50 microM) did not modify basal 45Ca uptake but strongly inhibited the influx of 45Ca induced by K+. 7. These results suggest that (+)-glaucine has non-selective alpha 1- and alpha 2-adrenoceptor blocking properties. At higher doses, (+)-glaucine shows calcium antagonist activity which may be responsible, at least in part, for the inhibition of the contractions induced by Ca2+ in calcium-free high-potassium medium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298818      PMCID: PMC2175806          DOI: 10.1111/j.1476-5381.1993.tb13904.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

Review 2.  Cellular mechanisms regulating [Ca2+]i smooth muscle.

Authors:  C van Breemen; K Saida
Journal:  Annu Rev Physiol       Date:  1989       Impact factor: 19.318

3.  Alpha 1-adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites.

Authors:  G Hanft; G Gross; J J Beckeringh; C Korstanje
Journal:  J Pharm Pharmacol       Date:  1989-10       Impact factor: 3.765

4.  Anti-spasmogenic and spasmolytic effects of BRL 34915: a comparison with nifedipine and nicorandil.

Authors:  J C Clapham; C Wilson
Journal:  J Auton Pharmacol       Date:  1987-09

5.  Alpha 1-adrenoceptors of rat myocardium: comparison of agonist binding and positive inotropic response.

Authors:  G Gross; G Hanft; C U Rugevics
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

6.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists.

Authors:  G Hanft; G Gross
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

8.  [Antinoradrenergic activity of raubasine on isolated thoracic aorta and vas deferens of rat (author's transl)].

Authors:  J Roquebert; P Gomond; P Demichel
Journal:  J Pharmacol       Date:  1981 Nov-Dec

9.  Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein.

Authors:  T C Hamilton; S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

10.  Pharmacological studies on dl-glaucine phosphate as an antitussive.

Authors:  Y Kasé; M Kawaguchi; K Takahama; T Miyata; I Hirotsu; T Hitoshi; Y Okano
Journal:  Arzneimittelforschung       Date:  1983
View more
  4 in total

1.  Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.

Authors:  J Cortijo; V Villagrasa; R Pons; L Berto; M Martí-Cabrera; M Martinez-Losa; T Domenech; J Beleta; E J Morcillo
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

3.  Study of the in vivo and in vitro cardiovascular effects of (+)-glaucine and N-carbethoxysecoglaucine in rats.

Authors:  F Orallo; A Fernández Alzueta; M Campos-Toimil; J M Calleja
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

4.  Glaucine inhibits breast cancer cell migration and invasion by inhibiting MMP-9 gene expression through the suppression of NF-κB activation.

Authors:  Hyereen Kang; Sung-Wuk Jang; Jhang Ho Pak; Sungbo Shim
Journal:  Mol Cell Biochem       Date:  2015-02-11       Impact factor: 3.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.